4.6 Article

NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition

Journal

ONCOGENESIS
Volume 2, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/oncsis.2013.24

Keywords

NeuroD1; neuroendocrine; TrkB; migration

Categories

Funding

  1. National Institutes of Health [R01DK55310, P50CA70907]
  2. Cancer Prevention and Research Institute of Texas (CPRIT)
  3. DOD PROSPECT
  4. Longenbaugh Foundation
  5. NIGMS pharmacological sciences training grant [5-T32 GM007062]
  6. NHMRC Biomedical Fellowship TSANZ/Allen & Hanburys Respiratory Research Fellowship [494511]

Ask authors/readers for more resources

The developmental transcription factor NeuroD1 is anomalously expressed in a subset of aggressive neuroendocrine tumors. Previously, we demonstrated that TrkB and neural cell adhesion molecule (NCAM) are downstream targets of NeuroD1 that contribute to the actions of neurogenic differentiation 1 (NeuroD1) in neuroendocrine lung. We found that several malignant melanoma and prostate cell lines express NeuroD1 and TrkB. Inhibition of TrkB activity decreased invasion in several neuroendocrine pigmented melanoma but not in prostate cell lines. We also found that loss of the tumor suppressor p53 increased NeuroD1 expression in normal human bronchial epithelial cells and cancer cells with neuroendocrine features. Although we found that a major mechanism of action of NeuroD1 is by the regulation of TrkB, effective targeting of TrkB to inhibit invasion may depend on the cell of origin. These findings suggest that NeuroD1 is a lineage-dependent oncogene acting through its downstream target, TrkB, across multiple cancer types, which may provide new insights into the pathogenesis of neuroendocrine cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biology

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

Ling Cai, Hongyu Liu, Fang Huang, Junya Fujimoto, Luc Girard, Jun Chen, Yongwen Li, Yu-An Zhang, Dhruba Deb, Victor Stastny, Karine Pozo, Christin S. Kuo, Gaoxiang Jia, Chendong Yang, Wei Zou, Adeeb Alomar, Kenneth Huffman, Mahboubeh Papari-Zareei, Lin Yang, Benjamin Drapkin, Esra A. Akbay, David S. Shames, Ignacio I. Wistuba, Tao Wang, Jane E. Johnson, Guanghua Xiao, Ralph J. DeBerardinis, John D. Minna, Yang Xie, Adi F. Gazdar

Summary: This study revealed the connection between immune phenotypes and NE scores, as well as the differences in immune gene expression between classic SCLC and variant SCLC. The research demonstrated the re-expression of MHC I in SCLC upon development of chemoresistance. These findings provide guidance for the design of treatment regimens in SCLC.

COMMUNICATIONS BIOLOGY (2021)

Article Oncology

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort

Rafal Dziadziuszko, Tony Mok, Solange Peters, Ji-Youn Han, Jorge Alatorre-Alexander, Natasha Leighl, Virote Sriuranpong, Maurice Perol, Gilberto de Castro Junior, Ernest Nadal, Filippo de Marinis, Osvaldo Aren Frontera, Daniel S. W. Tan, Dae Ho Lee, Hye Ryun Kim, Mark Yan, Todd Riehl, Erica Schleifman, Sarah M. Paul, Simonetta Mocci, Rajesh Patel, Zoe June Assaf, David S. Shames, Michael S. Mathisen, Shirish M. Gadgeel

Summary: The study demonstrated the clinical application of blood-based next-generation sequencing technology in ALK-positive NSCLC patients, showing good efficacy and safety of alectinib treatment. The research also investigated the treatment outcomes of patients with baseline CNS metastases and the relationship between circulating biomarkers and treatment response.

JOURNAL OF THORACIC ONCOLOGY (2021)

Article Oncology

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial

Shirish Gadgeel, Fred R. Hirsch, Keith Kerr, Fabrice Barlesi, Keunchil Park, Achim Rittmeyer, Wei Zou, Namrata Bhatia, Hartmut Koeppen, Sarah M. Paul, David Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark McCleland, David R. Gandara

Summary: This study suggests that both the SP142 and 22C3 assays have similar predictive value for the efficacy of atezolizumab in patients with metastatic non-small cell lung cancer. The use of atezolizumab was associated with greater survival regardless of the assay used to determine tumor PD-L1 status.

CLINICAL LUNG CANCER (2022)

Article Oncology

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, Jessica Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton

Summary: Atezolizumab monotherapy showed promising clinical activity in patients with TMB >= 16 mut/Mb tumors lacking other suitable treatment options and who were immunotherapy-naive at enrollment, regardless of microsatellite instability status. Limited activity was observed in tumors with TMB >= 10 and < 16 mut/Mb.

CANCER DISCOVERY (2022)

Article Oncology

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony Sk Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski

Summary: Atezolizumab combined with bevacizumab and chemotherapy is an effective first-line treatment in metastatic non-squamous non-small cell lung cancer subgroups with mKRAS and co-occurring STK11 and/or KEAP1 or TP53 mutations and/or high PD-L1 expression. Mutation of STK11 and/or KEAP1 can serve as poor prognostic indicators.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Cell Biology

UBR5 is a novel regulator of WNK1 stability

Ji-Ung Jung, Anwesha B. Ghosh, Svetlana Earnest, Staci L. Deaton, Melanie H. Cobb

Summary: The protein kinase WNK1 is involved in maintaining cellular ion homeostasis and its accumulation can lead to familial hypertension. This study investigates the degradation pathways of WNK1 and identifies UBR5 as a regulator of WNK1 protein stability that leads to lysosomal degradation.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2022)

Article Oncology

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil, Barzin Y. Nabet, Soeren Mueller, Hartmut Koeppen, Wei Zou, Jennifer Giltnane, Amelia Au-Yeung, Shyam Srivats, Jason H. Cheng, Chikara Takahashi, Patricia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William E. O'Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames

Summary: The study revealed that inhibitors of the PD-1/PD-L1 signaling axis have a significant overall survival benefit for non-small cell lung cancer (NSCLC) patients. Transcriptomic analysis and single-cell RNA sequencing showed that B and plasma cells play an important role in the efficacy of PD-L1 blockade in NSCLC.

CANCER CELL (2022)

Article Biochemistry & Molecular Biology

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chaes, Ticiana A. Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher S. R. Dakhil, Philip Stella, Yanling Jin, David S. Shames, Erica Schleifman, David A. Fabrizio, See Phan, Mark A. Socinski

Summary: In patients with non-small cell lung cancer, blood TMB shows potential as a predictive biomarker for first-line atezolizumab monotherapy, with higher ORR in the high bTMB group. However, the results for PFS were not statistically significant. Additionally, at 36.5-month follow-up, bTMB >= 16 was associated with longer OS compared to bTMB < 16.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft, Filiz Oezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michal Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric Toloza, Eric B. Haura, Ciaran J. McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone

Summary: This study examined the use of neoadjuvant atezolizumab in patients with resectable non-small cell lung cancer. It found that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but further studies are needed to confirm these findings.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters, Rafal Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Cheema, Manuel Cobo, Zoran Andric, Carlos H. Barrios, Masafumi Yamaguchi, Eric Dansin, Pongwut Danchaivijitr, Melissa Johnson, Silvia Novello, Michael S. Mathisen, Sarah M. Shagan, Erica Schleifman, Jin Wang, Mark Yan, Simonetta Mocci, David Voong, David A. Fabrizio, David S. Shames, Todd Riehl, David R. Gandara, Tony Mok

Summary: Selection of non-small cell lung cancer patients based on high blood-based tumor mutation burden did not improve clinical response, further research is needed.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

ERK2 Mutations Affect Interactions, Localization, and Dimerization

Clinton A. Taylor, Kevin W. Cormier, Ana Martin-Vega, Svetlana Earnest, Steve Stippec, Chonlarat Wichaidit, Melanie H. Cobb

Summary: The most frequent ERK2 mutation in cancers, E322K, is located in the common docking (CD) site, affecting its binding with activators, inactivating phosphatases, and substrates. Another mutation, D321N, also affects the CD site but less frequently. These gain-of-function mutations have been found to have subtle differences in behavior, such as increased nuclear retention and disrupted dimer interface.

BIOCHEMISTRY (2023)

Article Multidisciplinary Sciences

WNK1 controls endosomal trafficking through TRIM27-dependent regulation of actin assembly

Ji-Ung Jung, Melanie H. Cobb

Summary: The protein kinase WNK1 influences the trafficking and actin polymerization of membrane proteins. This study discovered a connection between WNK1 and TRIM27, which regulates endosomal actin polymerization. Depletion of WNK1 disrupted WASH ubiquitination and endosomal actin polymerization, affecting endosomal trafficking. Depletion of WNK1 or TRIM27 increased the degradation of EGFR in cancer cells.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Multidisciplinary Sciences

Modulating p38 MAPK signaling by proteostasis mechanisms supports tissue integrity during growth and aging

Wang Yuan, Yi M. Weaver, Svetlana Earnest, Clinton A. Taylor, Melanie H. Cobb, Benjamin P. Weaver

Summary: The authors found that the pool of non-phosphorylated p38 MAPK can modulate signaling to control growth, lysosome formation, and neuronal integrity. By altering the stoichiometry of non-phospho-p38, they enhanced PMK-1 signaling to promote tissue integrity and longevity. Their findings suggest that reducing the reservoir of non-phospho-p38 can enhance signaling without hyper-activation of stress response during aging.

NATURE COMMUNICATIONS (2023)

Review Biochemistry & Molecular Biology

Navigating the ERK1/2 MAPK Cascade

Ana Martin-Vega, Melanie H. Cobb

Summary: The RAS-ERK pathway is crucial for various biological processes and its aberrant activation is implicated in diseases such as cancer. This review focuses on the structure, activation, regulation, and mutational frequency of the pathway, with an emphasis on ERK1/2. The significance of scaffold proteins in kinase localization and interaction dynamics is highlighted, along with potential therapeutic approaches in this field.

BIOMOLECULES (2023)

Article Oncology

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

Wei Zou, Stephanie J. Yaung, Frederike Fuhlbrueck, Marcus Ballinger, Eric Peters, John F. Palma, David S. Shames, David Gandara, Yuqiu Jiang, Namrata S. Patil

Summary: In this study, the association between ctDNA MMPM levels at 6 weeks post-treatment and OS in advanced non-small-cell lung cancer patients treated with atezolizumab or docetaxel was investigated. The results suggest that ctDNA has the potential to serve as a noninvasive early liquid biopsy predictor for OS, highlighting the need for further studies to demonstrate its clinical utility.

JCO PRECISION ONCOLOGY (2021)

No Data Available